Ono T, Numata K, Nagate T, Mitsuhashi S, Inoue M
Episome Institute, Gunma, Japan.
Chemotherapy. 1996 May-Jun;42(3):159-69. doi: 10.1159/000239437.
The in vitro and in vivo antibacterial activities of clarithromycin (CAM), a new oral macrolide antibiotic, were compared with those of erythromycin (EM), josamycin (JM) and rokitamycin (RKM). The antibacterial spectrum and in vitro activities of CAM were similar to those of EM. Therapeutic efficacies of CAM against various experimental infections in mice--including systemic infections caused by gram-positive bacteria such as Staphylococcus aureus, Streptococcus pyogenes and Streptococcus pneumoniae, and subcutaneous abscess due to S. aureus, and bacterial pneumonia caused by S. pneumoniae--were superior to those of EM, JM and RKM. CAM exhibited higher serum levels than EM in mice after a single oral dose of 50 mg/kg.
将新型口服大环内酯类抗生素克拉霉素（CAM）的体内外抗菌活性与红霉素（EM）、交沙霉素（JM）和罗他霉素（RKM）进行了比较。CAM的抗菌谱和体外活性与EM相似。CAM对小鼠各种实验性感染的治疗效果——包括由革兰氏阳性菌如金黄色葡萄球菌、化脓性链球菌和肺炎链球菌引起的全身感染，由金黄色葡萄球菌引起的皮下脓肿，以及由肺炎链球菌引起的细菌性肺炎——优于EM、JM和RKM。单次口服50mg/kg后，CAM在小鼠体内的血清水平高于EM。
